JP5587541B2 - ノルオキシモルホン化合物の精製方法 - Google Patents
ノルオキシモルホン化合物の精製方法 Download PDFInfo
- Publication number
- JP5587541B2 JP5587541B2 JP2007554413A JP2007554413A JP5587541B2 JP 5587541 B2 JP5587541 B2 JP 5587541B2 JP 2007554413 A JP2007554413 A JP 2007554413A JP 2007554413 A JP2007554413 A JP 2007554413A JP 5587541 B2 JP5587541 B2 JP 5587541B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- group
- noroxymorphone
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 33
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical class O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 title claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 59
- -1 noroxymorphone compound Chemical class 0.000 claims description 56
- 238000005984 hydrogenation reaction Methods 0.000 claims description 35
- 239000000047 product Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 22
- 229960003086 naltrexone Drugs 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 229960004127 naloxone Drugs 0.000 claims description 13
- 239000000419 plant extract Substances 0.000 claims description 12
- 125000004185 ester group Chemical group 0.000 claims description 10
- 239000012535 impurity Substances 0.000 claims description 10
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 9
- 229960005118 oxymorphone Drugs 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 150000002148 esters Chemical group 0.000 claims description 6
- IFGIYSGOEZJNBE-KNLJMPJLSA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 IFGIYSGOEZJNBE-KNLJMPJLSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
- 239000000356 contaminant Substances 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims description 4
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 125000005587 carbonate group Chemical group 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 2
- 238000010626 work up procedure Methods 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- OPPSZLCGCWIRIA-MBPVOVBZSA-N 3,14-diacetyloxymorphone Chemical compound O([C@H]1C(CC[C@]23OC(C)=O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O OPPSZLCGCWIRIA-MBPVOVBZSA-N 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 9
- 239000000010 aprotic solvent Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007795 chemical reaction product Substances 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 2
- PCSQOABIHJXZMR-MGQKVWQSSA-O (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O PCSQOABIHJXZMR-MGQKVWQSSA-O 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical class 0.000 description 2
- 125000004399 C1-C4 alkenyl group Chemical class 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- UTWHNLJWWXJBLY-UHFFFAOYSA-N ethyl carbamoperoxoate Chemical compound CCOOC(N)=O UTWHNLJWWXJBLY-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229960002921 methylnaltrexone Drugs 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002941 palladium compounds Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 229910052703 rhodium Inorganic materials 0.000 description 2
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 1
- ZKLXUUYLEHCAMF-UHFFFAOYSA-N Oripavine Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(O)C5=C4C23C1O5 ZKLXUUYLEHCAMF-UHFFFAOYSA-N 0.000 description 1
- 240000004674 Papaver rhoeas Species 0.000 description 1
- 235000007846 Papaver rhoeas Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical class [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical class CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000002815 homogeneous catalyst Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- UJNZOIKQAUQOCN-UHFFFAOYSA-N methyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C)C1=CC=CC=C1 UJNZOIKQAUQOCN-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 239000002623 mu opiate receptor antagonist Substances 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- PENAXHPKEVTBLF-UHFFFAOYSA-L palladium(2+);prop-1-ene;dichloride Chemical class [Pd+]Cl.[Pd+]Cl.[CH2-]C=C.[CH2-]C=C PENAXHPKEVTBLF-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- UIYOVVYZPVVUMJ-UHFFFAOYSA-N tert-butyl carbamoyl carbonate Chemical compound CC(C)(C)OC(=O)OC(N)=O UIYOVVYZPVVUMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 description 1
- 229930003945 thebaine Natural products 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003624 transition metals Chemical group 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- DLQYXUGCCKQSRJ-UHFFFAOYSA-N tris(furan-2-yl)phosphane Chemical class C1=COC(P(C=2OC=CC=2)C=2OC=CC=2)=C1 DLQYXUGCCKQSRJ-UHFFFAOYSA-N 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
(a1)N−メチル基[式(II)の化合物のR1の定義に相当]を除去し、脱離基R3(R3は、R1について前述したものなどの脱離基であり、好ましくはアルキルオキシカルボニル、好ましくはエチルオキシカルボニルまたはBoc、好ましくはエチルオキシカルボニルである)によって置き換え;
(a2)脱離基R2およびR3を、段階(a)および(a1)から得られた反応生成物から脱離させても良く;
(b)段階(a)、(a1)および/または(a2)で得られた生成物のうちの少なくとも一つ、好ましくは段階(a1)または(a2)で得られた生成物のうちの一つ、好ましくは段階(a2)での生成物について、上記の選択的水素化反応を行い、
(c)純粋なノルオキシモルホン化合物を単離しても良い
ことを特徴とする方法に関するものでもある。
オキシモルホン20gを、tert−ブチルメチルエーテル10gおよび無水酢酸21g(3.24当量)の混合物に室温で懸濁させる。反応溶液を還流下に5時間加熱する。その後、冷却し、tert−ブチルメチルエーテル70gを加える。その懸濁液を再度還流温度まで加熱し、冷却して0〜4℃とし、沈殿が完了するまでさらに攪拌する。生成物を吸引濾過し、tert−ブチルメチルエーテルで洗浄し、90℃で減圧下に乾燥させて恒量とする。収量:23g(使用したオキシモルホンに基づいて91%);HPLC純度:98%、生成物は、微量(約1000ppm)のα,β−不飽和化合物を含み、3,8,14−トリアセチルオキシモルホンは検出できない。
オキシモルホン20gを、tert−ブチルメチルエーテル10gおよび無水酢酸21g(3.24当量)の混合物中に室温で懸濁させる。反応溶液を、最高30〜40℃で48時間加熱する。次に、冷却し、tert−ブチルメチルエーテル70gを加える。混合物を冷却して0〜4℃とし、沈殿が完了するまで攪拌する。生成物を吸引濾過し、tert−ブチルメチルエーテルで洗浄し、30℃で減圧下に乾燥させて恒量とする。収量:26.8g(使用したオキシモルホン基準で91%);HPLC純度:98%、生成物は微量の3,8,14−トリアセチルオキシモルホンを含む。
ジアセチルオキシモルホン30gを、有機溶媒(アセトニトリル74g)中にてクロルギ酸エチル66g(8当量)および不均一塩基(炭酸カリウム1当量)とともに懸濁させ、高温(65〜68℃)で数時間(24〜28時間)加熱する。反応終了後、アセトニトリルおよびクロルギ酸エチルを減圧下に留去する。アセトニトリル73gを残留物に加える。次に、不均一塩基(KHCO3/K2CO3)を室温で濾去する。減圧下にアセトニトリルを留去し、沈殿を完了させるために、tert−ブチルメチルエーテル60gを加える。還流温度まで加熱し、混合物を冷却して0〜5℃とし、さらに攪拌した後、沈殿固体を吸引濾過し、最初にtert−ブチルメチルエーテルで、次に水で洗浄する。無色生成物を、80℃で減圧下に乾燥させて恒量とする。HPLCによれば、生成物は>1000ppmのα,β−不飽和化合物を含む。
微量の3,8,14−トリアセチルオキシモルホンを含むジアセチルオキシモルホン20gを、tert−ブチルメチルエーテル20gおよび酢酸3〜5gの混合物中に室温で懸濁させる。反応溶液を70℃で10〜15時間加熱する。その後、冷却し、tert−ブチルメチルエーテル70gを加える。混合物を冷却して0〜4℃とし、沈殿が完了するまで攪拌する。生成物を吸引濾過し、tert−ブチルメチルエーテルで洗浄し、30℃で減圧下に乾燥させて恒量とする。収量:15.7g(使用したジアセチルオキシモルホンに基づいて91%);HPLC純度:98%、生成物は約1000ppmのα,β−不飽和化合物を含み、3,8,14−トリアセチルオキシモルホンは検出できない。
実施例2に従って製造された微量の3,8,14−トリアセチルオキシモルホンを含むジアセチルオキシモルホン20gを、室温で氷酢酸60gに溶かす。含水パラジウム/活性炭0.6g(乾燥物基準で10%Pd、含水量約50%)をそれに加える。次に、内部温度50〜60℃および2.7バールで水素ガスを導入する。その水素化後、触媒を濾去し、溶液を減圧下に濃縮して半量とする。次に、MTBEを加え、混合物を冷却して0〜4℃とする。生成物を吸引濾過し、MTBEで洗浄し、70℃で真空乾燥する。純度:98%;α,β−不飽和化合物も3,8,14−トリアセチルオキシモルホンも検出できない。収率85%(使用したジアセチルオキシモルホンに基づいたジアセチルオキシモルホン)。
実施例3に従って製造したジアセチルオキシモルホンカーバメート30gを、室温で氷酢酸60gに溶かす。含水パラジウム/活性炭0.6g(乾燥物基準で10%Pd、含水量約50%)をそれに加える。次に、内部温度50〜60℃および2.7バールで水素ガスを導入する。水素化後、触媒を濾去し、減圧下に溶液を濃縮して半量とする。その濃縮氷酢酸溶液に、3倍体積の40%硫酸を加える。還流下に、カーバメートを煮沸して、遊離アミンを得る。この途中で、生成物は硫酸塩として析出する。形成された塩を濾過し、少量の冷エタノールで洗浄する。得られた固体を水/エタノールに溶かし、アンモニア水溶液でpHを9とする。このpHで、遊離ノルオキシモルホンは沈殿し、それを濾過する。α,β−不飽和副生成物はHPLC分析によって全く検出されない。収率:70〜75%(使用したジアセチルオキシモルホンカーバメートに基づいて)。
Claims (18)
- 植物抽出物から得られたものであり、本質的に下記式(II)のノルオキシモルホン化合物からなり、不純物として、すくなくとも1つの式(Ia)および(Ib):
のα,β−不飽和ノルオキシモルホン化合物、ならびにそれらのα−置換およびβ−置換アルコールであるさらなる汚染物であるノルオキシモルホン化合物を含む粗生成物からノルオキシモルホン化合物を製造する方法において、前記式(II)のノルオキシモルホン化合物が、下記式(II):
(式中、R1は、水素もしくはメチルである)で表される化合物であり、
(a)前記粗生成物を、混合物中に存在するヒドロキシル基を式−OR2の脱離基に変換する反応(式中、R2は前記脱離基の導入基である)で処理し、(b)前記導入基R2を式−OR2の脱離基から分離させ、次に(c)得られた混合物について選択的水素化を行って、前記α,β−不飽和ノルオキシモルホン化合物のα,β−位に飽和結合を形成し、残留する前記導入基R2を式−OR2の脱離基からそれぞれ分離させ、次に(d)純粋なノルオキシモルホン化合物を単離することを特徴とする方法。 - 前記段階(b)で導入された基R2を式−OR2の脱離基から分離させてから前記選択的水素化段階(c)を行う請求項1に記載の方法。
- 前記段階(a)および段階(b)が、得られた生成物を非水系媒体中で単離する後処理をさらに含む、請求項1または2に記載の方法。
- 残留する前記段階(b)で導入された基R2を、前記選択的水素化後に式−OR2の脱離基から分離させる請求項1または3に記載の方法。
- 前記水素化[段階(c)]後になお存在する前記導入基R2を加水分解によって式−OR2の脱離基から分離させる請求項1〜4のいずれか1項に記載の方法。
- 前記脱離基のR2が、(C1〜C4)−アルキルオキシカルボニルまたはフェニルオキシカルボニルである請求項1〜5のいずれか1項に記載の方法。
- 前記脱離基のR2が、エチルオキシカルボニル、イソブチルオキシカルボニル、またはtert−ブチルオキシカルボニル(Boc)である請求項6に記載の方法。
- 前記脱離基のR2が、エチルオキシカルボニルまたはtert−ブチルオキシカルボニル(Boc)である請求項7に記載の方法。
- 前記式−OR2の前記脱離基が、エステル部分である請求項1〜5のいずれか1項に記載の方法。
- 前記式−OR2の前記脱離基が、ホルミルエステル基、アセチルエステル基、トリクロロアセチルエステル基、トリフルオロアセチルエステル基、ベンゾイルエステル基、置換されていても良いベンジルエステル基である、すなわち前記−OR2基中のR2がホルミル、メチルカルボニル、トリクロロメチルカルボニル、トリフルオロメチルカルボニル、フェニルカルボニル、置換されていても良いフェニルカルボニルであるか、−OR2が、R2がメチルスルホニル、ベンジルスルホニルもしくはp−トルエンスルホニルであるスルホン酸のエステル部分である請求項9に記載の方法。
- −OR2が炭酸エステル部分であり;R2が、(C1〜C8)−アルキルオキシカルボニルまたはフェニルオキシカルボニルである請求項1〜5のいずれか1項に記載の方法。
- R2が、エチルオキシカルボニル、イソブチルオキシカルボニル、tert−ブチルオキシカルボニル(Boc)またはシクロヘキシルオキシカルボニルである請求項11に記載の方法。
- −R2がエチルオキシカルボニルまたはtert−ブチルオキシカルボニル(Boc)である請求項12に記載の方法。
- 固体としての前記植物抽出物が、合計で少なくとも70重量%の前記式(II)の化合物を含み、前記α,β−不飽和ノルオキシモルホン化合物に対する前記式(II)の化合物の比率が0.200重量%〜0.001重量%の前記α,β−不飽和ノルオキシモルホン化合物に対して99.800重量%〜99.999重量%の前記式(II)のノルオキシモルホン化合物という範囲にあり、前記抽出物中に存在する全ての固体が合計で100重量%となる請求項1〜13のいずれか1項に記載の方法。
- 段階(d)で得られた前記ノルオキシモルホンをさらに処理して、ナルトレキソンもしくはナロキソンまたはこれら化合物の塩またはこれら化合物の4級誘導体を得る請求項1〜14のいずれか1項に記載の方法。
- 前記化合物の塩またはこれら化合物の4級誘導体が、該化合物の塩酸塩、臭化水素酸塩、メトクロライドまたはメトブロマイドである請求項15に記載の方法。
- 前記化合物の塩またはこれら化合物の4級誘導体が、ナルトレキソン塩酸塩、ナルトレキソン臭化水素酸塩、ナルトレキソンメトクロライドまたはナルトレキソンメトブロマイドである請求項16に記載の方法。
- 段階(d)で得られた純粋なオキシモルホン/ノルオキシモルホン化合物中のα,β−不飽和ノルオキシモルホン化合物の濃度が10ppm未満である請求項1〜17のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CHPCT/CH05/000076 | 2005-02-11 | ||
PCT/CH2005/000076 WO2006084389A1 (de) | 2005-02-11 | 2005-02-11 | Verfahren zur reinigung von noroxymorphon-verbindungen |
PCT/CH2006/000087 WO2006084412A1 (de) | 2005-02-11 | 2006-02-09 | Verfahren zur reinigung von noroxymorphon-verbindungen |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008530036A JP2008530036A (ja) | 2008-08-07 |
JP5587541B2 true JP5587541B2 (ja) | 2014-09-10 |
Family
ID=35044741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007554413A Active JP5587541B2 (ja) | 2005-02-11 | 2006-02-09 | ノルオキシモルホン化合物の精製方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8227609B2 (ja) |
EP (1) | EP1851226B1 (ja) |
JP (1) | JP5587541B2 (ja) |
CN (1) | CN101115757B (ja) |
CA (1) | CA2597350C (ja) |
DK (1) | DK1851226T3 (ja) |
ES (1) | ES2529045T3 (ja) |
RU (1) | RU2401270C2 (ja) |
WO (2) | WO2006084389A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871779B2 (en) | 2006-03-02 | 2014-10-28 | Mallinckrodt Llc | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
JP2010504325A (ja) * | 2006-09-20 | 2010-02-12 | マリンクロット インコーポレイテッド | 置換モルフィナン−6−オン、並びにその塩および中間体の調製 |
CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
EP2073636B1 (en) * | 2006-10-17 | 2012-09-05 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
EP2121699B1 (en) | 2006-12-04 | 2012-09-19 | Noramco, Inc. | Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone |
ATE543823T1 (de) * | 2006-12-04 | 2012-02-15 | Noramco Inc | Verfahren zur reduzierung von unreinheiten in oxycodonbase |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
CN101781303A (zh) * | 2007-03-06 | 2010-07-21 | 马林克罗特公司 | 季n-烷基吗啡喃生物碱盐的制备方法 |
US9040726B2 (en) * | 2007-03-06 | 2015-05-26 | Mallinckrodt Llc | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts |
JP5373764B2 (ja) * | 2007-04-16 | 2013-12-18 | マリンクロッド エルエルシー | 触媒性水素転移反応を使用する新規なオピエート還元 |
FR2923484B1 (fr) | 2007-11-09 | 2012-11-09 | Sanofi Aventis | Procede de preparation de composes morphiniques |
EP2062896A1 (en) | 2007-11-26 | 2009-05-27 | Siegfried Ltd. | Demethylation of 14-hydroxy substituted alkaloid derivatives |
US8158793B2 (en) | 2007-11-26 | 2012-04-17 | Siegfried Ltd. | Demethylation of 14-hydroxy substituted alkaloid derivatives |
EP2244766A1 (en) * | 2007-12-07 | 2010-11-03 | Mallinckrodt Inc. | Power injector syringe mounting system |
EP2231674A1 (en) * | 2007-12-17 | 2010-09-29 | Mallinckrodt Inc. | Processes for the preparation of normorphinan salts |
WO2009122436A2 (en) * | 2008-03-31 | 2009-10-08 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
PL2896614T3 (pl) * | 2008-05-27 | 2018-02-28 | Mallinckrodt Llc | Sposoby i związki do wytwarzania normorfinanów |
AU2014200890B2 (en) * | 2008-05-27 | 2016-02-04 | SpecGx LLC | Processes and compounds for the preparation of normorphinans |
WO2010028004A2 (en) | 2008-09-03 | 2010-03-11 | Mallinckrodt Inc. | Substituted berbines and processes for their synthesis |
TWI471289B (zh) | 2010-06-11 | 2015-02-01 | Rhodes Technologies | 使三級胺進行n-脫烷反應之方法 |
CA2802295C (en) | 2010-06-11 | 2016-09-20 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
EP2420503A1 (en) * | 2010-07-27 | 2012-02-22 | Universität Innsbruck | Process for the synthesis of 14-oxygenated morphinan-6-ones |
CN102351869B (zh) * | 2011-10-24 | 2013-11-13 | 江苏奥赛康药业股份有限公司 | 一种溴化甲基纳曲酮的制备方法 |
GB201313915D0 (en) * | 2013-08-02 | 2013-09-18 | Johnson Matthey Plc | Process |
ES2784690T3 (es) | 2013-12-05 | 2020-09-29 | Univ Bath | Nuevos compuestos opioides y sus usos |
CN103626782B (zh) * | 2013-12-13 | 2016-07-13 | 山东新华制药股份有限公司 | 溴甲纳曲酮的制备方法 |
EP3166948A1 (en) * | 2014-07-09 | 2017-05-17 | Rhodes Technologies Inc. | Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions |
CN105753875A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种乙酰化Delta-7甲基纳曲酮甲酸盐及其制备方法 |
CN105753876A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种Delta-7溴甲纳曲酮的制备方法 |
CN105753874A (zh) * | 2014-12-15 | 2016-07-13 | 北大方正集团有限公司 | 一种Delta-7甲基纳曲酮甲酸盐及其制备方法 |
EP3252055B1 (en) | 2016-05-31 | 2018-09-19 | Alcaliber Investigacion Desarrollo e Innovacion SLU | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
AU2021368196A1 (en) * | 2020-11-02 | 2023-06-22 | Rhodes Technologies | Process for purifying noroxymorphone |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2727805A1 (de) | 1977-06-21 | 1979-01-04 | Goedecke Ag | Verfahren zur herstellung von oxynormorphon |
IT1199871B (it) * | 1984-03-27 | 1989-01-05 | Mallinckrodt Inc | Procedimento per la preparazione di norossimorfone dalla morfina e composti intermedi per tale procedimento |
JP2694156B2 (ja) * | 1989-10-16 | 1997-12-24 | アメリカ合衆国 | N−ノル中間体を介するノルテバイン、ノルモルフィン、ノルオキシモルフォン鏡像異性体の全合成 |
HU224914B1 (en) * | 1994-05-31 | 2006-04-28 | Mallinckrodt Chemical Inc | Process for the preparation of nalbuphine having not more then 1% levels of beta-epimer |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
-
2005
- 2005-02-11 WO PCT/CH2005/000076 patent/WO2006084389A1/de not_active Application Discontinuation
-
2006
- 2006-02-09 ES ES06704529.4T patent/ES2529045T3/es active Active
- 2006-02-09 CA CA2597350A patent/CA2597350C/en active Active
- 2006-02-09 WO PCT/CH2006/000087 patent/WO2006084412A1/de active Application Filing
- 2006-02-09 DK DK06704529T patent/DK1851226T3/da active
- 2006-02-09 US US11/815,784 patent/US8227609B2/en active Active
- 2006-02-09 JP JP2007554413A patent/JP5587541B2/ja active Active
- 2006-02-09 RU RU2007133670/04A patent/RU2401270C2/ru not_active IP Right Cessation
- 2006-02-09 CN CN2006800045237A patent/CN101115757B/zh not_active Expired - Fee Related
- 2006-02-09 EP EP06704529.4A patent/EP1851226B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
RU2401270C2 (ru) | 2010-10-10 |
JP2008530036A (ja) | 2008-08-07 |
WO2006084412A9 (de) | 2007-09-20 |
CN101115757A (zh) | 2008-01-30 |
WO2006084412A1 (de) | 2006-08-17 |
CA2597350A1 (en) | 2006-08-17 |
RU2007133670A (ru) | 2009-03-20 |
EP1851226A1 (de) | 2007-11-07 |
ES2529045T3 (es) | 2015-02-16 |
US8227609B2 (en) | 2012-07-24 |
CA2597350C (en) | 2014-04-29 |
EP1851226B1 (de) | 2014-11-26 |
CN101115757B (zh) | 2010-12-22 |
DK1851226T3 (da) | 2015-03-02 |
WO2006084389A1 (de) | 2006-08-17 |
US20090270624A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5587541B2 (ja) | ノルオキシモルホン化合物の精製方法 | |
US8134002B2 (en) | Process for preparing oxymorphone | |
AU2005288728B2 (en) | Preparation of opiate analgesics by reductive alkylation | |
AU2009233315B2 (en) | An improved process for the preparation of morphinane analogues | |
AU2011274361B2 (en) | Process for the synthesis and purification of oxycodone | |
CA2692433C (en) | Methods for n-demethylation of morphine and tropane alkaloids | |
HUE034668T2 (hu) | Eljárás morfinán-származékok szintézisére és azok intermedierjei | |
CN103880903A (zh) | 一种泰乐菌素类大环内酯及其衍生物的制备方法 | |
JP2010531813A (ja) | テバインのモルヒネ誘導体への変換 | |
RU2297419C2 (ru) | Производное 14-гидроксинорморфинона, производное морфинона, производное морфина, способы получения производного 14-гидроксинорморфинона, производное морфинона, нороксиморфона | |
EP2705040B1 (en) | Process for the preparation of morphine analogs via metal catalyzed n-demethylation/functionalization and intramolecular group transfer | |
JP5270091B2 (ja) | 7−アルキル−10−ヒドロキシ−20(s)−カンプトテシンを調製するためのプロセス | |
CA2644881A1 (en) | Demethylation of 14-hydroxy substituted alkaloid derivatives | |
EP3024834B1 (en) | Preparation of saturated ketone morphinan compounds by catalytic isomerisation | |
KR20230127222A (ko) | 모르핀으로부터 노르옥시모르폰의 합성을 위한 신규의제조방법 | |
JPH0791252B2 (ja) | 7‐ジメチルアミノ‐6‐デメチル‐6‐デオキシテトラサイクリンの製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130702 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140724 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5587541 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |